On October 8, Recursion Pharmaceuticals, Inc. fell 8.21% in regular trading, trading at $4.245 per share, with turnover of $120 million.

The decline follows last month's amended data license agreement with Tempus AI, which replaced up to $84 million in discretionary payments over two years with $42 million in committed payments over three years. While the restructuring provides longer-term revenue visibility, SEC filings also revealed that Recursion's right to terminate the agreement for convenience has been removed, limiting its strategic flexibility. Recursion separately granted Tempus a nonexclusive, worldwide license to its proprietary RNA sequencing model.

Within the Biotechnology sector, performance was mixed. Moderna rose 2.09%, AbbVie rose 2.6%, Vaxcyte rose 0.19%, while Natera fell 0.35% and Twist Bioscience fell 5.02%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)